Jounce Therapeutics

$5.20 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates Inducible T cell CO-Stimulator (ICOS) and is in a Phase II trial.

Stock Analysis

last close $5.11
1-mo return -21.6%
3-mo return -40.1%
avg daily vol. 265.08T
52-week high 14.84
52-week low 4.43
market cap. $258M
forward pe -
annual div. -
roe -20.3%
ltg forecast -
dividend yield -
annual rev. $64M
inst own. 70%
baraka

Subscribe now for daily local and international financial news

Subscribe